Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.32 USD
Change Today -0.0159 / -4.68%
Volume 99.8K
APPY On Other Exchanges
APPY is not on other exchanges.
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

venaxis inc (APPY) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - $2.09
52 Week Low
09/30/15 - $0.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VENAXIS INC (APPY)

Related News

No related news articles were found.

venaxis inc (APPY) Related Businessweek News

No Related Businessweek News Found

venaxis inc (APPY) Details

Venaxis, Inc., an in vitro diagnostic company, engages in the development and commercialization of products for unmet diagnostic and therapeutic needs. The company’s research, development, and commercial activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

24 Employees
Last Reported Date: 03/30/15
Founded in 2000

venaxis inc (APPY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $375.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $254.9K
Commercial Consultant
Total Annual Compensation: $260.6K
Compensation as of Fiscal Year 2014.

venaxis inc (APPY) Key Developments

Venaxis Seeks Acquisitions

Venaxis, Inc. (NasdaqCM:APPY) is looking for acquisition opportunities. Steve Lundy, President and Chief Executive Officer of Venaxis, said, "we were considering options to possibly acquire or gain access to assets beyond our core focus of appendicitis diagnostic development and commercialization. Over the last few months, we have identified numerous companies with what we believe have attractive assets and opportunities."

Venaxis, Inc. - Shareholder/Analyst Call

To provide an update on regulatory and business matters

John H. Landon to Retire as Director of Venaxis, Inc., Effective June 1, 2015

Venaxis, Inc. announced that at the Board meeting held on May 6, 2015, John H. Landon, a director since December 2008, announced his intention to retire from his Board service effective June 1, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APPY:US $0.32 USD -0.0159

APPY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APPY.
View Industry Companies

Industry Analysis


Industry Average

Valuation APPY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 69.7x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENAXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at